Clinical Trial Update: CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM [Phase 1]

View source ↗

Summary

Trial update for a Phase 1 CART-T therapy called CART-EGFR-IL13Ra2 in EGFR-amplified recurrent glioblastoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CART-EGFR-IL13Ra2

Snippet

Sponsor: University of Pennsylvania | Conditions: Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING